Your browser doesn't support javascript.
Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience.
Tascini, Carlo; Sermann, Giovanni; Pagotto, Alberto; Sozio, Emanuela; De Carlo, Chiara; Giacinta, Alessandro; Sbrana, Francesco; Ripoli, Andrea; Castaldo, Nadia; Merelli, Maria; Cadeo, Barbara; Macor, Cristiana; De Monte, Amato.
  • Tascini C; U.O. Malattie Infettive, Dipartimento di Medicina dell'Università di Udine, Università di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Via Pozzuolo, 330, 33100, Udine, Italy. c.tascini@gmail.com.
  • Sermann G; SOC Anestesia e Rianimazione Uno, Università di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Via Pozzuolo, 330, 33100, Udine, Italy.
  • Pagotto A; U.O. Malattie Infettive, Dipartimento di Medicina dell'Università di Udine, Università di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Via Pozzuolo, 330, 33100, Udine, Italy.
  • Sozio E; U.O. Malattie Infettive, Dipartimento di Medicina dell'Università di Udine, Università di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Via Pozzuolo, 330, 33100, Udine, Italy.
  • De Carlo C; Pronto Soccorso e Medicina d'urgenza / HDU Livorno, Azienda USL, Toscana Nord Ovest, 33100, Livorno, Italy.
  • Giacinta A; U.O. Malattie Infettive, Dipartimento di Medicina dell'Università di Udine, Università di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Via Pozzuolo, 330, 33100, Udine, Italy.
  • Sbrana F; U.O. Malattie Infettive, Dipartimento di Medicina dell'Università di Udine, Università di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Via Pozzuolo, 330, 33100, Udine, Italy.
  • Ripoli A; U.O. Lipoapheresis and Center for Inherited Dyslipidemias, Fondazione Toscana "Gabriele Monasterio", Via Moruzzi, 1, 56124, Pisa, Italy. francesco.sbrana@ftgm.it.
  • Castaldo N; Deep Health Unit, Fondazione Toscana "Gabriele Monasterio", Via Moruzzi, 1, 56124, Pisa, Italy.
  • Merelli M; U.O. Malattie Infettive, Dipartimento di Medicina dell'Università di Udine, Università di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Via Pozzuolo, 330, 33100, Udine, Italy.
  • Cadeo B; U.O. Malattie Infettive, Dipartimento di Medicina dell'Università di Udine, Università di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Via Pozzuolo, 330, 33100, Udine, Italy.
  • Macor C; U.O. Malattie Infettive, Dipartimento di Medicina dell'Università di Udine, Università di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Via Pozzuolo, 330, 33100, Udine, Italy.
  • De Monte A; SOC Anestesia e Rianimazione Uno, Università di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Via Pozzuolo, 330, 33100, Udine, Italy.
Intern Emerg Med ; 16(3): 669-675, 2021 04.
Article in English | MEDLINE | ID: covidwho-898127
ABSTRACT
The emerging outbreak of the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide. We prescribed some promising medication to our patients with mild to moderate pneumonia due to SARS-CoV-2, however such drugs as chloroquine, hydrossichloroquine, azithromycin, antivirals (lopinavir/ritonavir, darunavir/cobicistat) and immunomodulating agents (steroids, tocilizumab) were not confirmed as effective against SARS-CoV2. We, therefore, started to use auto-hemotherapy treated with an oxygen/ozone (O2/O3) gaseous mixture as adjuvant therapy. In Udine University Hospital (Italy) we performed a case-control study involving hospitalized adult patients with confirmed COVID-19 with mild to moderate pneumonia. Clinical presentations are based upon clinical phenotypes identified by the Italian Society of Emergency and Urgency Medicine (SIMEU-Società Italiana di Medicina di Emergenza-Urgenza) and patients that met criteria of phenotypes 2 to 4 were treated with best available therapy (BAT), with or without O3-autohemotherapy. 60 patients were enrolled in the study 30 patients treated with BAT and O2/O3 mixture, as adjuvant therapy and 30 controls treated with BAT only. In the group treated with O3-autohemotherapy plus BAT, patients were younger but with more severe clinical phenotypes. A decrease of SIMEU clinical phenotypes was observed (2.70 ± 0.67 vs. 2.35 ± 0.88, p = 0.002) in all patients during hospitalization but this clinical improvement was statistically significant only in O3-treated patients (2.87 ± 0.78 vs. 2.27 ± 0.83, p < 0.001), differently to the control group (2.53 ± 0.51 vs. 2.43 ± 0.93, p = 0.522). No adverse events were observed associated with the application of O2/O3 gaseous mixture. O2/O3 therapy as adjuvant therapy could be useful in mild to moderate pneumonia due to SARS-CoV-2. Randomized prospective study is ongoing [Clinical Trials.gov ID Z7C2CA5837].
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ozone / Pneumonia, Viral / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Intern Emerg Med Journal subject: Emergency Medicine / Internal Medicine Year: 2021 Document Type: Article Affiliation country: S11739-020-02542-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Ozone / Pneumonia, Viral / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Intern Emerg Med Journal subject: Emergency Medicine / Internal Medicine Year: 2021 Document Type: Article Affiliation country: S11739-020-02542-6